Muhammad Ehtisham, MD
Internal Medicine · Pawtucket, RINPI 1407222433
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (46.2%), education and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 63.4% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2023 at $5,080 and has fallen 64.6% since, to $1,799 in 2025. Among internal medicine clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 111 payments — averaging $91.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- Covidien LP$2K
- GSK$443
- AstraZeneca$354
- Boston Scientific$196
- Mylan Specialty L.p.$104
- plus $363 from 8 others
What the payments were for
- Travel & lodging$4,70646%
- Food & beverage$2,28222%
- Education$3,00629%
- Gifts$2032%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 28 | $6,463 |
| Covidien LP | 9 | $2,275 |
| GSK | 29 | $443 |
| AstraZeneca | 19 | $354 |
| Boston Scientific | 5 | $196 |
| Mylan Specialty L.p. | 6 | $104 |
| Regeneron Healthcare Solutions, Inc. | 4 | $91 |
| Philips North America LLC | 4 | $84 |
| Boehringer Ingelheim | 2 | $59 |
| Advanced Respiratory, Inc | 1 | $34 |
| Sanofi | 1 | $30 |
| Mallinckrodt Hospital Products Inc. | 1 | $25 |
| Insmed, Inc. | 1 | $23 |
| Tactile Systems Technology Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$5,756
- superDimension$1,897
How this compares
$10,197 in reported general payments places this provider in the 95th percentile of 808 internal medicine providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 1,133 | $804,934 |
| Dupixent PenDupilumab | 101 | $375,709 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 383 | $260,622 |
| RemicadeInfliximab | 15 | $130,287 |
| NucalaMepolizumab | 23 | $84,386 |
| XolairOmalizumab | 23 | $74,826 |
| Ambrisentan | 21 | $66,148 |
| FasenraBenralizumab | 12 | $65,316 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 120 | $63,184 |
| Spiriva RespimatTiotropium Bromide | 107 | $58,544 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 57 | $27,276 |
| Varenicline Tartrate | 84 | $19,463 |
| SymbicortBudesonide/Formoterol Fumarate | 66 | $18,552 |
| Atrovent HfaIpratropium Bromide | 25 | $17,642 |
| Incruse ElliptaUmeclidinium Bromide | 46 | $16,055 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta, Breo Ellipta | $443 | $945,6171,291 claims |
| AstraZenecaBreztri Aerosphere, Fasenra, Symbicort, Airsupra | $354 | $355,382484 claims |
| Boehringer IngelheimCombivent Respimat, Spiriva Respimat | $59 | $121,729227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 808 internal medicine providers in Rhode Island.
Other internal medicine in Pawtucket
- Jeffrey BaronPawtucket$19K
- Omeed SaniPawtucket$16K
- Amber GulPawtucket$6K
- Rafael Liporaci LucenaPawtucket$4K
- William BeliveauJohnson$951K
- Katarzyna Gilek-SeibertProvidence$131K
- Randall InghamProvidence$100K
- Frank D'alessandroLincoln$93K
- Gregory AllenCranston$38K
- Richard RuggieriProvidence$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.